Navigation Links
Biosensors Completes Spectrum Dynamics Assets Acquisition
Date:5/26/2013

SINGAPORE, May 26, 2013 /PRNewswire/ --  Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced the completion of its acquisition of substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions.  

The deal consideration is approximately US$51 million, with potential earn-out payments upon fulfilling certain performance criteria. Under the terms of the deal, the two companies will also create a joint venture aimed at developing future non-cardiac applications. Biosensors expects the transaction to have minimal impact on its 2014 fiscal year financial results, with the potential to be moderately accretive to its earnings in the following fiscal year. 

"The capacity to uncover and diagnose reversible ischemia prior to catheterization with precision has turned into an essential issue in the treatment of cardiovascular disease. Spectrum Dynamics' advanced imaging systems will facilitate doctors to more effectively establish the appropriate course of treatment for their patients," said Prof. Shlomo Ben-Haim , Co-Founder and Chairman of Spectrum Dynamics. "Biosensors is one of the leading developers of drug-eluting stents. By becoming part of Biosensors' growing family, we hope to actively contribute towards its future growth potential by exploring more opportunities and applications together for better diagnostic solutions for patients."

Dr Jack Wang , CEO of Biosensors said, "We are pleased to have completed this acquisition. With substantially all assets of Spectrum Dynamics under the ownership and management of Biosensors, we are well-positioned to further increase our presence in the global cardiovascular interventional field with this exciting cardiovascular diagnostic technology. We look forward to working closely with the elite team from Spectrum Dynamics. Together, we will continue to expand Biosensors' product offering and build the company into a world class medical device enterprise."


For Biosensors International Group, Ltd
Mr. Wong Teck Yenn
Director, Investor Relations

Tel: (65) 6213 5777
Email: ir@biosensors.com

About Biosensors International Group, Ltd

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents and the recent launch of our Axxess™ self-expanding bifurcation drug-eluting stent, we are rapidly emerging as a leader in the global coronary stent market. The development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer-free stent abluminally coated with BA9, received CE Mark Approval in January 2013.

For more information, please visit www.biosensors.com.

About Spectrum Dynamics
Spectrum Dynamics LLC is a pioneering medical device company focused on personalized molecular imaging and applications. Spectrum Dynamics aims to revolutionize the practice of nuclear cardiology, and eventually all nuclear medicine applications, by dramatically enhancing workflow and providing new clinical applications not possible with conventional technology.

For more information, please visit www.spectrum-dynamics.com

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.


'/>"/>
SOURCE Biosensors International Group, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biosensors to Acquire Assets of Spectrum Dynamics
2. Frost & Sullivan Acknowledges that PKCs Biosensors are Expected to Become the New Industry Standard in Pathogen Testing
3. Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2013
4. Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013
5. MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy
6. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
7. Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
8. Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting And Stapling Device
9. Kite Pharma Completes $35 Million Series A Preferred Stock Financing
10. Vertellus Specialties Completes Upgrades for API Niacin Manufacture
11. Haemonetics Completes Hemerus Medical, LLC Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
Breaking Medicine Technology:
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 , ... ... has settled over 175,000 debt accounts, translating to in excess of $835 million in ... card debt and other unsecured loans are some of the categories of debt settled ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, ... light filter. When we’re born, Nature gives us a full supply of melanin ... age, we continuously lose this natural glare-reducing pigment; however, around the age of thirty, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets a ... by Xlibris on July of 2014). This book details the recent advances and techniques ... that benefit people who have lost all of their natural teeth . , ...
(Date:9/19/2017)... Pendleton, California (PRWEB) , ... September 19, 2017 , ... ... members and their families, announces the release of a series of videos and a ... epidemic for service members in the United States as part of its ongoing mission. ...
Breaking Medicine News(10 mins):